A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Women with Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) Is Indicated

Full Title

A Phase 1/2 Study of Chemo-immunotherapy with Toll-like Receptor 8 Agonist Motolimod (VTX-2337) and anti-PD-L1 Antibody MEDI4736 in Subjects with Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated

Purpose

This study is assessing motolimod and MEDI4736 in women with recurrent, platinum-resistant ovarian cancer who are scheduled to receive pegylated liposomal doxorubicin (PLD). MEDI4736 and PLD are given intravenously, while motolimod is given subcutaneously.

Eligibility

This study is for patients who:

  • Have recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after first- or second-line platinum-based chemotherapy, for which treatment with PLD is indicated.
  • Have not had prior exposure to doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736, or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies.
  • Are age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Roisin O'Cearbhaill at 646-888-4227.

Protocol

15-184

Phase

I/II

Investigator

Co-Investigators

Locations